Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

Review of the Treatment of Mycosis Fungoides and Sézary Syndrome: A Stage-Based Approach

(2017) Steven M. Horwitz et al.   Journal of the National Comprehensive Cancer Network

Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma

(2011) Francine M Foss   Expert Opinion on Drug Metabolism & Toxicology

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial

(2011) Christopher G. Azzoli et al.   Journal of Thoracic Oncology

Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma

(2010) H. Miles Prince et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients With Relapsed or Refractory Non-Hodgkin's or Hodgkin's Lymphoma

(2009) D R Mould et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

(2009) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY